2026-03-23 20:08:30
Bionano Genomics Reports Q4 2025 Results with Revenue Decline of 3%
Expected Stock impact: Slightly Negative
Bionano Genomics, Inc. (Nasdaq: BNGO) has released its financial results for the fourth quarter and full year ended December 31, 2025, revealing a total revenue of $8.0 million for Q4 2025, which marks a 3% decrease from $8.2 million in the same quarter of 2024. The decline in revenue is attributed to a slight drop in consumables and software revenues, which decreased by 1%. The previous year’s figures included $2.8 million in instrument revenue, while the current quarter reported $2.7 million. Additionally, the company sold 7,554 nanochannel array flowcells in Q4 2025, a 6% decrease from the 8,058 sold in Q4 2024. Despite these challenges, Bionano installed 9 new optical genome mapping (OGM) systems, bringing the total installed base to 387, a 4% increase from the previous year. The company reported a gross margin of 43%, up from 42% in Q4 2024, and reduced operating expenses by 22% to $11.9 million. For the full year 2025, Bionano reported total revenue of $28.5 million, a 7% decrease from $30.8 million in 2024. The company ended the year with cash and cash equivalents totaling $29.6 million. Looking ahead, Bionano anticipates Q1 2026 revenue in the range of $6.5 to $6.7 million and full-year revenue guidance between $30 to $33 million. The company remains optimistic about the growth of OGM as a standard for genome-wide structural variant analysis, bolstered by a 47% increase in the Clinical Lab Fee Schedule payment determination for OGM use in hematologic malignancies.
